A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
SmokersFormer Smokers
Interventions
DRUG

lamivudine

Lamivudine (Epivir) is a drug used typically to treat HIV and Hepatitis B Virus (HBV). It has not been studied when given in combination with spermidine.

DRUG

rapamycin

Rapamycin (Rapamune, Sirolimus) is an FDA-approved drug and indicated for use as an immune modulator.

BEHAVIORAL

Exercise Regimen

All experimental groups will receive an exercise regimen combining high-intensity interval training (HIIT) (targeting aerobic fitness) and resistance training (targeting strength and skeletal muscle mass preservation). The HIIT exercise component will consist of 2 sessions per week totaling 20 minutes per session. The resistance training component will consist of 3 sessions per week totaling 40 minutes per session.

DIETARY_SUPPLEMENT

Spermidine

Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. Participants will take an oral dosage of 2mg/day for 180 days.

Trial Locations (1)

10029

RECRUITING

Mount Sinai Hospital, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER